Original Article
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
N Engl J Med 2008; 359:1786-1801October 23, 2008
- Abstract
Background
Alemtuzumab, a humanized monoclonal antibody that targets CD52 on lymphocytes and monocytes, may be an effective treatment for early multiple sclerosis.
Methods
In this phase 2, randomized, blinded trial involving previously untreated, early, relapsing–remitting multiple sclerosis, we assigned 334 patients with scores of 3.0 or less on the Expanded Disability Status Scale and a disease duration of 3 years or less to receive either subcutaneous interferon beta-1a (at a dose of 44 μg) three times per week or annual intravenous cycles of alemtuzumab (at a dose of either 12 mg or 24 mg per day) for 36 months. In September 2005, alemtuzumab therapy was suspended after immune thrombocytopenic purpura developed in three patients, one of whom died. Treatment with interferon beta-1a continued throughout the study.
Results
Alemtuzumab significantly reduced the rate of sustained accumulation of disability, as compared with interferon beta-1a (9.0% vs. 26.2%; hazard ratio, 0.29; 95% confidence interval [CI], 0.16 to 0.54; P<0.001) and the annualized rate of relapse (0.10 vs. 0.36; hazard ratio, 0.26; 95% CI, 0.16 to 0.41; P<0.001). The mean disability score on a 10-point scale improved by 0.39 point in the alemtuzumab group and worsened by 0.38 point in the interferon beta-1a group (P<0.001). In the alemtuzumab group, the lesion burden (as seen on T2-weighted magnetic resonance imaging) was reduced, as compared with that in the interferon beta-1a group (P=0.005). From month 12 to month 36, brain volume (as seen on T1-weighted magnetic resonance imaging) increased in the alemtuzumab group but decreased in the interferon beta-1a group (P=0.02). Adverse events in the alemtuzumab group, as compared with the interferon beta-1a group, included autoimmunity (thyroid disorders [23% vs. 3%] and immune thrombocytopenic purpura [3% vs. 1%]) and infections (66% vs. 47%). There were no significant differences in outcomes between the 12-mg dose and the 24-mg dose of alemtuzumab.
Conclusions
In patients with early, relapsing–remitting multiple sclerosis, alemtuzumab was more effective than interferon beta-1a but was associated with autoimmunity, most seriously manifesting as immune thrombocytopenic purpura. The study was not powered to identify uncommon adverse events. (ClinicalTrials.gov number, NCT00050778.)
Media in This Article
Figure 1
Enrollment and Outcomes.Figure 2
Efficacy Outcome Measures Regarding Disability and Relapse at 36 Months.Article Activity
- Article
Multiple sclerosis typically follows a relapsing–remitting course, but most patients eventually convert to a secondary progressive phase characterized by deficits that increase in the absence of further relapses. This clinical evolution reflects the complex interplay of focal inflammation, demyelination, and axonal degeneration in the central nervous system. Current disease-modifying treatments decrease the frequency of relapse and modestly reduce the accumulation of disability but have not been shown to prevent secondary progression.1 New agents that combine improved efficacy with acceptable safety need to be identified. The humanized monoclonal antibody alemtuzumab (Campath-1H; Campath, or MabCampath; Genzyme) targets CD52 on lymphocytes and monocytes. Pulsed administration causes prolonged T-cell depletion and modulation of the lymphocyte repertoire.2
Since 1991, studies of alemtuzumab in the treatment of patients with secondary progressive multiple sclerosis have suggested efficacy in the suppression of relapse but not in preventing the continued progression of disability.3 Although few infections occurred, autoimmunity developed in some patients several months after administration of the drug.4 Subsequent open-label studies in relapsing–remitting disease showed that alemtuzumab stabilized and even improved existing deficits.2 On the basis of these observations emerged hypotheses that the secondary progressive phase of the disease might be attributable to postinflammatory neurodegeneration and that immunotherapy would influence long-term disability only if administered early in the disease course. These concepts informed the design of our blinded, phase 2, randomized trial comparing two doses of alemtuzumab with subcutaneous interferon beta-1a (Rebif, EMD Serono and Pfizer) in previously untreated patients with early, relapsing–remitting multiple sclerosis.
Methods
Patients
From December 2002 to July 2004, a total of 334 patients underwent randomization at 49 centers in Europe and the United States. The last patient started treatment in September 2004. Each patient provided written informed consent.
Eligibility criteria were a diagnosis of relapsing–remitting multiple sclerosis (on the basis of the McDonald criteria5) with an onset of symptoms no more than 36 months before the time of screening; at least two clinical episodes during the previous 2 years; a score of 3 or less on the Expanded Disability Status Scale (EDSS),6 which ranges from 0 to 10, with higher scores indicating greater disability; and one or more enhancing lesions, as seen on at least one of up to four monthly cranial magnetic resonance imaging (MRI) scans. Key exclusion criteria were previous disease-modifying treatments, a history of clinically significant autoimmunity, or the presence of serum antithyrotropin-receptor antibodies.
Study Design and Randomization
Eligible patients were randomly assigned in a 1:1:1 ratio to receive alemtuzumab (at a dose of either 12 mg per day or 24 mg per day) or interferon beta-1a with the use of the Pocock and Simon minimization algorithm7 to balance the study groups with regard to age (<30 years or ≥30 years), sex, and baseline EDSS score (<2.0 or ≥2.0). Alemtuzumab was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians' discretion if the CD4+ T-cell count was ≥100×106 cells per liter). Interferon beta-1a (at a dose of 44 μg) was administered subcutaneously three times weekly after dose escalation. All patients received 1 g of intravenous methylprednisolone for 3 days at baseline and at months 12 and 24, coinciding with infusion cycles as premedication for those receiving alemtuzumab. Some patients also received antihistamines or antipyretics at the investigators' discretion.
Study Outcomes and Procedures
EDSS scores were determined quarterly in a blinded fashion by a neurologist who also adjudicated possible relapses. Patients wore clothing that covered injection sites. The effectiveness of blinding was assessed at the end-of-study visit. Safety was assessed quarterly by the treating neurologist, who was aware of study-group assignment.
The coprimary measures of efficacy were the time to sustained accumulation of disability and the rate of relapse. Disability was assessed according to the ordinal EDSS score. A sustained accumulation of disability was defined as an increase of at least 1.5 points for patients with a baseline score of 0 and of at least 1.0 point for patients with a baseline score of 1.0 or more; all scores were confirmed twice during a 6-month period. The onset of a sustained level of disability was timed to the first recorded increase in the EDSS score aside from relapse. Patients with an increased level of disability could be discontinued from the study. A relapse was defined as new or worsening symptoms with an objective change in neurologic examination attributable to multiple sclerosis that lasted for at least 48 hours, that were present at normal body temperature, and that were preceded by at least 30 days of clinical stability.
Secondary outcomes were the proportion of patients who did not have a relapse, changes in lesion burden (as seen on T2-weighted MRI), and brain volume (as measured by the Losseff method on T1-weighted MRI8). MRI scans were performed annually and interpreted by a neuroradiologist at Perceptive Informatics who was unaware of assignments to study groups.
Thyroid function and levels of antithyrotropin-receptor antibodies and lymphocyte subpopulations were measured quarterly at a central laboratory (Cirion Clinical Trial Services and Charles River Laboratories). Serum-binding antibodies against alemtuzumab were measured with the use of a validated enzyme-linked immunosorbent assay (ELISA)9 at BioAnaLab. There was no active monitoring for progressive multifocal leukoencephalopathy. Criteria for the diagnosis of immune thrombocytopenia were a single confirmed platelet count of fewer than 50,000 per microliter without clumping or a platelet count of more than 50,000 but fewer than 100,000 per microliter on at least two consecutive occasions during a period of at least 1 month, with normal hemoglobin, neutrophil, and eosinophil counts; an absence of splenomegaly; and a normal peripheral-blood smear (apart from thrombocytopenia). All adverse events with an onset up to 36 months are reported. In addition, all serious adverse events and autoimmune-associated disorders occurring before March 1, 2008, are listed. A subsequent adverse event of Burkitt's lymphoma not associated with Epstein–Barr virus (EBV) is also included in this report.
Statistical Analysis
On the basis of the literature,2-16 we determined that 285 patients would be needed to provide a power of 75% to detect a treatment effect at 36 months, assuming a rate of sustained disability of 12% in the alemtuzumab group and of 30% in the group receiving interferon beta-1a with a two-sided test and a significance level of 2% (with a Bonferroni adjustment for two alemtuzumab groups and a significance level of 1% for the comparison of relapse rates). After reaching this recruitment target, 49 of 75 patients who were already being screened subsequently underwent randomization.
Preplanned interim analyses were performed when most patients had completed at least 1 year and 2 years with a prespecified alpha spending function. Disclosure of these results formed part of safety announcements by the sponsor in September 2005 and 2006. After the interim analyses, P values of less than 0.016 and 0.004 were considered to have statistical significance for the rates of sustained disability and relapse, respectively (for details, see the Supplementary Appendix, available with the full text of this article at www.nejm.org).
Treatment effects were compared with respect to the time to sustained accumulation of disability with the use of a proportional-hazards model and to the rate of relapse with the use of the Andersen–Gill model with robust variance estimation.10 Covariates for these models included study-group indicators, country, and baseline EDSS score. The proportion of patients with relapse-free survival was assessed with the use of logistic regression. The estimated percentage of patients with sustained disability or relapse was generated by the Kaplan–Meier method. The annualized rate of relapse was estimated with the use of Poisson regression. The number of patients who would need to be treated with alemtuzumab instead of interferon beta-1a to prevent one patient from having a relapse or sustained disability was calculated according to the proportion of patients who did not have these outcomes at month 36.11 Comparisons of EDSS scores were based on a repeated-measures analysis of covariance. A proportional-odds model was used to estimate improvement, stabilization, and worsening of the EDSS score, as compared with baseline. The percent change from baseline on MRI was analyzed with the use of the Wilcoxon–Mann–Whitney test and the multivariate Wei–Lachin test12,13 during the entire 36-month period. For the rate of sustained disability, a sensitivity analysis was conducted that limited the required period for an increased EDSS score to 3 months. Fisher's exact test and Poisson regression were used for the analysis of adverse events and event rates, respectively. The reported P values are two-sided and were not adjusted for multiple testing. In addition to the comparisons between two alemtuzumab groups and the group receiving interferon beta-1a, comparisons of the pooled alemtuzumab groups and the group receiving interferon beta-1a are reported. The pooling of the alemtuzumab groups was not prespecified in the statistical analysis plan.
The protocol was designed by the lead academic authors and was approved by local review boards or the ethics committee at each center. Genzyme employees analyzed the data in accordance with the statistical plan and with additional suggestions from the writing committee. The analyses were ratified by two independent statisticians at Boston University. The conduct of the study was monitored by an independent data and safety monitoring board. The lead academic authors vouch for the completeness and veracity of the data and analyses.
Results
Study Population
Of 334 patients who underwent randomization, 111 were assigned to receive subcutaneous interferon beta-1a three times weekly, and 223 were assigned to receive annual cycles of alemtuzumab, with 113 receiving 12 mg per day and 110 receiving 24 mg per day. One patient who received alemtuzumab was included in the safety analysis but was excluded from the efficacy analyses because the initial diagnosis of multiple sclerosis was incorrect, and the patient received the diagnosis of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) during the study. Baseline demographic and clinical characteristics were similar in the three treatment groups (Table 1Table 1
Baseline Characteristics of the Patients.). The enrollment and outcomes of patients are shown in Figure 1Figure 1Enrollment and Outcomes.. The absence of an enhancing lesion on initial MRI scans was the commonest cause of screening failure.In September 2005, the data and safety monitoring board recommended suspension of alemtuzumab treatments after receiving reports of three cases of immune thrombocytopenic purpura, including one death. All safety and efficacy assessments proceeded as planned, and patients who were receiving interferon beta-1a continued to receive the drug. At the time of dose suspension, only 2 eligible patients (1%) had not received the second cycle of alemtuzumab at month 12, whereas 155 patients (75%) were precluded from receiving the third cycle of alemtuzumab at month 24. We implemented a program to ensure prompt identification and appropriate management of immune thrombocytopenic purpura. This program included education for patients and physicians, monthly blood counts, and regular contact with patients, which included discussion about symptoms and signs of immune thrombocytopenic purpura. Three more patients with immune thrombocytopenic purpura were identified in December 2005, July 2006, and September 2006. Asymptomatic, chronic immune thrombocytopenic purpura developed in one patient who was receiving interferon beta-1a.
More patients discontinued interferon beta-1a than alemtuzumab, principally because of a lack of efficacy and adverse events, so that only 59% of the original group of patients receiving interferon beta-1a completed the 36-month study, as compared with 83% of patients receiving alemtuzumab. At the end of the study review, 90% and 91% of raters remained unaware of assignments to the group receiving interferon beta-1a and the group receiving alemtuzumab, respectively.
Clinical Efficacy
There were no significant differences between the groups receiving either 12 mg or 24 mg of alemtuzumab on any outcome measure or adverse event. Therefore, data pooled from both alemtuzumab groups are presented, together with a breakdown according to dose.
Disability
As compared with interferon beta-1a, alemtuzumab reduced the risk of sustained disability by 71% (hazard ratio, 0.29; 95% confidence interval [CI], 0.16 to 0.54; P<0.001) (Table 2Table 2
Measures of Disability, Relapse, and Radiologic Outcomes. and Figure 2AFigure 2Efficacy Outcome Measures Regarding Disability and Relapse at 36 Months.). For the 12-mg dose, the risk of sustained disability was reduced by 75% (hazard ratio, 0.25; 95% CI, 0.11 to 0.57; P<0.001); for the 24-mg dose, the risk reduction was 67% (hazard ratio, 0.33; 95% CI, 0.16 to 0.69; P=0.003). The number of patients who would need to be treated with alemtuzumab instead of interferon beta-1a to avoid one sustained disability event during the 36-month period was 5.8 (5.6 for the 12-mg dose and 6.0 for the 24-mg dose). In sensitivity analysis of the risk of sustained disability at 3 months, the risk reduction was 64% (hazard ratio, 0.36; 95% CI, 0.21 to 0.60; P<0.001).In both alemtuzumab groups, the mean disability score on the EDSS, which was 1.9 points at baseline, improved by 0.39 point (95% CI, 0.23 to 0.55) at 36 months: 0.32 point for the 12-mg dose (P=0.006) and 0.45 point for the 24-mg dose (P=0.001). During the same time, the mean disability score worsened by 0.38 point (95% CI, 0.13 to 0.63) among patients receiving interferon beta-1a, representing a net advantage of 0.77 point (95% CI, 0.48 to 1.06; P<0.001) among patients receiving alemtuzumab (Table 2 and Figure 2C). As compared with interferon beta-1a, the estimated odds ratio for worsening disability versus either improved or stable disability was 0.41 (95% CI, 0.24 to 0.69) for the 12-mg dose of alemtuzumab and 0.33 (95% CI, 0.19 to 0.56) for the 24-mg dose (P<0.001 for both comparisons).
Relapse
As compared with interferon beta-1a, alemtuzumab reduced the rate of relapse by 74% (hazard ratio, 0.26; 95% CI, 0.16 to 0.41; P<0.001) (Table 2 and Figure 2B); both alemtuzumab doses were effective, with a reduction of 69% (95% CI, 48 to 82) for the 12-mg dose and 79% (95% CI, 60 to 89) for the 24-mg dose (P<0.001 for both comparisons). The annualized relapse rate at 36 months was 0.36 for interferon beta-1a and 0.10 for alemtuzumab (0.11 for the 12-mg dose and 0.08 for the 24-mg dose). The proportion of patients who remained relapse-free at 36 months was 52% for interferon beta-1a and 80% for alemtuzumab (77% for the 12-mg dose and 84% for the 24-mg dose; P<0.001 for both comparisons) (Table 2). The number of patients who would need to be treated with alemtuzumab instead of interferon beta-1a to prevent 1 patient from having a relapse at 36 months was 3.5 (3.9 and 3.1 for the 12-mg dose and 24-mg dose, respectively).
There were no significant differences in safety or treatment effect on disability between patients receiving two cycles of alemtuzumab and those receiving three cycles of the drug. However, there was evidence of the waning of treatment efficacy on the rate of relapse. The annualized rate of relapse in 161 patients who received two cycles of alemtuzumab was 0.16 in months 24 to 36, an increase from 0.07 for months 0 to 12 and 0.06 for months 12 to 24. This rate was significantly reduced, as compared with the rate of 0.34 in patients receiving interferon beta-1a between months 24 and 36 (P=0.01). Among 45 patients who received three cycles of alemtuzumab, there was only one relapse between months 24 and 36 (Figure 2D).
Efficacy on MRI
From baseline to 36 months, there was a reduction in the volume of lesions, as seen on T2-weighted MRI, in all three study groups (Table 2). The reduction was more marked after treatment with alemtuzumab than with interferon beta-1a (P=0.005), with significant reductions from baseline at months 12 (P=0.01) and 24 (P=0.005). The differences in median change at month 36 were not significant. Of note, the sample size for the 36-month analyses was reduced because of the number of patients who discontinued the study and the 26 patients who had missing or technically deficient MRI scans. The reduction in brain volume between baseline and month 36 was significantly less among patients receiving alemtuzumab than among those receiving interferon beta-1a (−0.5% and −1.8%, respectively; P=0.05). Recognizing that atrophy measures may be confounded by early suppression of inflammatory space-occupying lesions, we analyzed brain volume between months 12 and 36; this measure was reduced by 0.2% among patients receiving interferon beta-1a but was increased by 0.9% in those receiving alemtuzumab (P=0.02) (Table 2).
On clinical and MRI outcomes, alemtuzumab remained superior to interferon beta-1a after subgroup analyses according to study-site location, baseline EDSS score, lesion load on T2-weighted MRI, cerebral volume on T1-weighted MRI, sex, race, and age of patients (data not shown).
Safety and Side Effects
Almost all patients reported at least one adverse event, and the number who had serious adverse events was also similar among the three study groups (Table 3Table 3
Adverse Events (Safety Population). and the Supplementary Appendix). There were two deaths, both in the alemtuzumab group. One patient who had several preexisting cardiac risk factors died of cardiovascular disease. The other death was attributable to immune thrombocytopenic purpura. Three cancers (non–EBV-associated Burkitt's lymphoma, breast cancer, and cervical cancer in situ) were reported in patients in the alemtuzumab group, with onset ranging from 22 to 64 months after the first annual cycle; among patients receiving interferon beta-1a, one case of colon cancer was reported at 36 months (Table 3).Serious infusion reactions occurred in three patients (1.4%) in the alemtuzumab group and led to discontinuation in one patient (0.5%). Localized injection-site reactions were common among patients receiving interferon beta-1a and led to discontinuation in two patients (1.9%). Abnormal liver-function tests were seen in 2.3% of patients in the alemtuzumab group and in 15.0% of those receiving interferon beta-1a, causing discontinuation of interferon beta-1a in three patients and grade 4 hepatic failure in one patient.
Mild-to-moderate infections, especially of the respiratory tract, were more common among patients in the alemtuzumab group than in those receiving interferon beta-1a. Recurrent oral herpes simplex virus type 1 was seen in three patients immediately after each cycle of alemtuzumab. Inactive tuberculosis was identified incidentally in one patient receiving the 24-mg dose of alemtuzumab. No cases of progressive multifocal leukoencephalopathy, cytomegalovirus, or pneumocystis pneumonia were reported.
Immune thrombocytopenic purpura developed in six patients (2.8%) receiving alemtuzumab and one patient (0.9%) receiving interferon beta-1a (P=0.43). The index patient suffered a fatal brain hemorrhage before diagnosis. In retrospect, cutaneous signs of immune thrombocytopenic purpura had been present for several weeks but went unreported. Of the six patients receiving alemtuzumab in whom immune thrombocytopenic purpura developed, four were receiving the 24-mg dose (three patients after two cycles and one after three) and two were receiving the 12-mg dose (both after three cycles). Remission of immune thrombocytopenic purpura occurred without treatment in one patient, after corticosteroid therapy in two patients, and after rituximab therapy in two patients. Grade 2 thrombocytopenia developed in one patient after 3 months of receiving interferon beta-1a; the condition persisted despite the withdrawal of interferon beta-1a and remained at grade 1 at the end of the study after reintroduction of interferon beta-1a.
Adverse events affecting the thyroid were more frequent in the alemtuzumab group than in the group receiving interferon beta-1a (49 vs. 3) (Table 3); these events were associated with thyroid autoantibodies in 96% of affected patients and occurred up to 30 months after the last dose of a study drug. Three patients (1.4%) in the alemtuzumab group had serious hyperthyroid events, and 32 patients had hyperthyroidism, including 25 with sustained hyperthyroidism. Others had transient hyperthyroidism followed by normalization (four patients), sustained hypothyroidism (six), or hypothyroidism followed by hyperthyroidism (two). Four patients underwent thyroid ablation with radioactive iodine, and 24 were treated with antithyroid agents (3 only temporarily). Primary hypothyroidism developed in 10 patients. In total, 18 patients required long-term thyroid-replacement therapy. Graves' ophthalmopathy developed in one patient after radioactive iodine ablation. (Numbers of patients were derived from in-depth case analyses and may differ from numbers of adverse events reported by investigators, as listed in Table 3.)
Immunologic Investigations
Alemtuzumab rapidly depleted lymphocytes after each treatment cycle. Lymphocyte reconstitution was similar for both doses. B-cell numbers returned to normal between 3 and 6 months. T-cell counts rose slowly and remained subnormal for the duration of the study; the median time for recovery of CD4+ lymphocytes was 3 months for 100×106 cells per liter; the time ranged from 6 to 9 months for 200×106 cells per liter. Alemtuzumab-binding antibodies above the prespecified threshold of 2000 U per milliliter were detected in 1 of 208 patients (0.5%) and 51 of 194 patients (26.3%) at 12 and 24 months, respectively. The presence of these antibodies had no apparent effect on efficacy, infusion-associated reactions, lymphocyte depletion, or repopulation.
Discussion
Among previously untreated patients with early, relapsing–remitting multiple sclerosis, alemtuzumab reduced the risk of sustained accumulation of disability by 71% and the risk of relapse by 74% (P<0.001 for both), as compared with interferon beta-1a. Efficacy was maintained over 36 months, even though 72% of alemtuzumab-treated patients did not receive the planned third cycle of therapy at month 24 because of safety concerns. The reduction in the lesion load on T2-weighted MRI was greater among patients receiving alemtuzumab than among those receiving interferon beta-1a, although the difference at 36 months was not significant; comparisons were limited by missing MRI data and the high discontinuation rate for interferon beta-1a. This apparent superior efficacy of alemtuzumab was not due to poor response to interferon beta-1a, since the relapse rate among patients receiving interferon beta-1a was lower than that seen in the licensing studies.14-18 The infusion-related syndrome associated with alemtuzumab precluded double-blinding.19 Therefore, we used a rater who was unaware of treatment assignments for efficacy outcomes, as advocated by the American Academy of Neurology,20 and confirmed successful maintenance of blinding throughout the study.
Although our study suggests that alemtuzumab is more effective than interferon beta-1a when given at the earliest stages of relapsing–remitting multiple sclerosis, our findings raise the difficult issue of exposing young adults who have little disability to a drug having potentially serious adverse effects. Our phase 2 trial was not designed to assess the long-term safety of alemtuzumab, nor was it powered to detect uncommon adverse events. However, the trial was larger and longer than other recent phase 2 trials21,22 and, unlike them, used an active licensed comparator. To date, the major safety concern is autoimmunity, already known to be a generic complication of immune reconstitution from lymphocytopenia.23,24 Thyroid autoimmunity was observed, as reported previously.4
Immune thrombocytopenic purpura caused the death of one patient. After the report of two further cases, the data and safety monitoring board suspended the administration of alemtuzumab between September 2005 and May 2007. Risk minimization measures effectively identified subsequent patients with immune thrombocytopenic purpura, and such measures should be considered mandatory for the safe future use of alemtuzumab. Immune thrombocytopenic purpura was seen in 2.8% of patients receiving alemtuzumab and 0.9% of those receiving interferon beta-1a. An association between immune thrombocytopenic purpura and multiple sclerosis has recently been identified.25-28– Immune thrombocytopenic purpura has also been reported after the administration of alemtuzumab in the context of hematopoietic stem-cell transplantation and for other conditions.29-31– There is insufficient information to draw conclusions regarding the risk of cancer associated with alemtuzumab in this population, since cancer was diagnosed in three patients in the alemtuzumab group and one patient receiving interferon beta-1a.
Mean disability scores improved among patients in the alemtuzumab group, as first seen in our open-label study of alemtuzumab,2 but worsened among those receiving interferon beta-1a. If improvements in disability after alemtuzumab are sustained, there would be important implications for the management of multiple sclerosis. An improvement of 0.39 EDSS point from a baseline score of 2.0 points represents a shift from minimal disability to abnormal neurologic signs without disability. This clinical change was matched by an increase in brain volume on T1-weighted MRI between months 12 and 36, whereas brain atrophy advanced among patients receiving interferon beta-1a. A possible mechanism may be the secretion of neurotrophins by lymphocytes that are regenerated after the administration of alemtuzumab.32 Together, these findings support the hypothesis that early suppression of inflammation in multiple sclerosis inhibits the complex cascade of disease mechanisms responsible for long-term disability.
Supported by Genzyme and Bayer Schering Pharma.
Dr. Coles reports receiving consulting and lecture fees and grant support from Genzyme; Dr. Compston, receiving consulting and lecture fees and grant support from Genzyme and lecture fees from Bayer Schering Pharma; Dr. Selmaj, receiving consulting fees from Genzyme, Biogen Idec, and Biopartners and lecture fees from Schering, Novartis, and Biogen Idec; and Drs. Lake, Moran, Margolin, and Tandon and Ms. Norris, being employees of Genzyme and having an equity interest in the company. No other potential conflict of interest relevant to this article was reported.
The members of the writing group (Alasdair J. Coles, Ph.D., F.R.C.P., and D. Alastair S. Compston, F.Med.Sci., Ph.D., University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom; Krzysztof W. Selmaj, M.D., Ph.D., Department of Neurology, Medical University of Lodz, Lodz, Poland; and Stephen L. Lake, Sc.D., Susan Moran, M.D., M.S.C.E., David H. Margolin, M.D., Ph.D., Kim Norris, B.Sc., and P.K. Tandon, Ph.D., Genzyme, Cambridge, MA) assume responsibility for the overall content and integrity of the article.
We thank the following Genzyme employees for their assistance in study operations and data analysis: D. Boisvert, R. Clark, R. Dhanjal, J. Haas, O. Haider, A. Feleaga, K. Hoffman, G. Newgard, T. Rios, M. Rizzo, and Q. Yu.
Source Information
Address reprint requests to Drs. Coles and Compston at the Department of Neurology, Box 165, Addenbrooke's Hospital, Cambridge CB2 2QQ, United Kingdom, or at ajc1020@medschl.cam.ac.uk or alastair.compston@medschl.cam.ac.uk.
Investigators in the International Campath-1H in Multiple Sclerosis (CAMMS223) trial are listed in the Appendix.
Appendix
The following researchers participated in the study: Data and Safety Monitoring Board: H. Panitch (chair), University of Vermont, Burlington; E. Anaissie, University of Arkansas for Medical Sciences, Little Rock; D. Cines, University of Pennsylvania, Philadelphia; L. DeGroot, Brown University, Providence, RI; F. Dorsey, Franklin, ME; T. Phillips, Texas Neurology, Dallas; J. Simon, Portland Veterans Affairs Medical Center, Portland, OR. Investigators and Study Centers: Croatia: V. Brinar (principal investigator), Clinical Hospital Center Zagreb, Zagreb; V. Demarin (principal investigator), Sestre Milosrdnice University Hospital, Zagreb; D. Janculjak (principal investigator), Clinical Hospital Osijek, Osijek; J. Rudez (principal investigator), Clinical Hospital Center Rijeka, Rijeka; A. Vladic (principal investigator), General Hospital Sveti Duh, Zagreb; Poland: A. Czlonkowska (principal investigator), D. Mirowska-Guzel, Institute of Psychiatry and Neurology, Warsaw; W. Kozubski (principal investigator), Medical Academy (Poznan), Poznan; H. Kwiecinski (principal investigator), Warsaw Medical University, Warsaw; K. Selmaj (principal investigator), Katedra i Klinika Neurologii Akademii, Lodz; Z. Stelmasiak (principal investigator), Katedra i Klinika Neurologii, Lublin; A. Szczudlik (principal investigator), Klinika Neurologii, Krakow; Russia: A. Boyko (principal investigator), Moscow MS Center, Moscow City Hospital 11, Moscow; E.I. Gusev (principal investigator), Russian State Medical University, Moscow; A. Skoromets (principal investigator), St. Petersburg State Pavlov Medical, St. Petersburg; I. Stolyarov (principal investigator), Institute of the Human Brain, St. Petersburg; N. Yakhno (principal investigator), Moscow City Hospital 61, Moscow; I. Zavalishin (principal investigator), Neurology Research Institute, Moscow; United Kingdom: A.J. Coles (principal investigator), D.A.S. Compston (principal investigator), J. Shawcross, J. Jones, A.L. Cox, Addenbrooke's Hospital, Cambridge; United States: A. Bass (principal investigator), D. Wenzel, Neurology Center of San Antonio, San Antonio, TX; V. Biton (principal investigator), Clinical Trials, Little Rock, AR; M. Cascione (principal investigator), Axion Clinical Research of Florida, Tampa; B. Cleeremans (principal investigator), NervePro Research, Irvine, CA; J. Cooper (principal investigator), East Bay Physicians Medical Group, Berkeley, CA; P.K. Coyle (principal investigator), D. Madigan, SUNY at Stony Brook, Stony Brook, NY; B. Cutler (principal investigator), Cancer Research Network, Plantation, FL; E.J. Fox (principal investigator), L. Mayer, R. Tyer, Central Texas Neurology Consultants, Round Rock; S. Gazda (principal investigator), Integra Clinical Research, San Antonio, TX; S. Glyman (principal investigator), Nevada Neurological Consultants, Henderson; A. Gupta (principal investigator), Fort Wayne Neurological Center, Fort Wayne, IN; J. Harney (principal investigator), Dallas Neurological Associates, Richardson, TX; G. Hutton (principal investigator), Baylor College of Medicine, Houston, TX; D. Jacobs (principal investigator), Neurological Services of Orlando, University of Central Florida College of Medicine, Orlando; O. Khan (principal investigator), R. Lisak, A. Tselis, Wayne State University School of Medicine, Detroit; J. Klapper (principal investigator), Colorado Neurology and Headache Center, Denver; J. Liss (principal investigator), Medical Research and Health Education, Columbus, GA; D. Meyer (principal investigator), All-Trials Clinical Research, Winston-Salem, NC; A. Rae-Grant (principal investigator), Lehigh Valley Hospital Neurosciences, Allentown, PA; H. Rossman (principal investigator), W. Boudouris, M. Belkin, R. Pierce, Michigan Institute for Neurological Disorders, Farmington; W. Royal (principal investigator), University of Maryland, Baltimore; R. Shubin (principal investigator), D. Sider, Neuro-Therapeutics, Pasadena, CA; M. Stein (principal investigator), MS Service, Walnut Creek, CA; B. Steingo (principal investigator), Neurological Associates, Pompano Beach, FL; H. Sullivan (principal investigator), Michigan Medical, Grand Rapids; C. Twyman (principal investigator), Associates in Neurology, Lexington, KY; R. Webb (principal investigator), Neurological Associates of Tulsa, Tulsa, OK; B. Weinshenker (principal investigator), B.M. Keegan, D. Rauchwarter, Mayo Clinic, Rochester, MN; D. Wingerchuk (principal investigator), J. Carter, Mayo Clinic Arizona, Scottsdale; S. Wray (principal investigator), Knoxville, TN; D. Wynn (principal investigator), N. Allen, C. Nagar, D. O'Brien, Consultants in Neurology, Northbrook IL. MRI Central Reading Center: J. Paskavitz, Perceptive Informatics, Waltham, MA; P. Schaefer, Massachusetts General Hospital, Boston. Thyroid Advisory Panel: L. DeGroot, Brown University, Providence RI; W. Valente, University of Maryland School of Medicine, Baltimore. Immune Thrombocytopenic Purpura Advisory Panel: D. Beardsley, Yale University School of Medicine, New Haven, CT; J. Bussel, Weill Cornell Medical College of Cornell University, New York; D. Cines, University of Pennsylvania, Philadelphia; M. Goldberg, Genzyme, Cambridge, MA; R. MacMillan, Scripps Cancer Center, La Jolla, CA; D. Scadden, Massachusetts General Hospital, Boston. Independent Statisticians: R.B. D'Agostino, M. Pencina, Boston University, Boston. Study Manager: G. Gonzales, Genzyme. Scientific Advisers: H. Waldmann, G. Hale, University of Oxford, Oxford, United Kingdom.
- References
References
1
Compston A, Coles A. Multiple sclerosis. Lancet (in press).
2
Coles AJ ,Cox A ,Le Page E , et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006;253:98-108
CrossRef | Web of Science | Medline3
Moreau T ,Thorpe J ,Miller D , et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 1994;344:298-301[Erratum, Lancet 1994;344:486.]
CrossRef | Web of Science | Medline4
Coles AJ ,Wing MG ,Smith S , et al. Pulsed monoclonal antibody treatment and autoimmunity thyroid disease in multiple sclerosis. Lancet 1999;354:1691-1695
CrossRef | Web of Science | Medline5
McDonald WI ,Compston A ,Edan G , et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127
CrossRef | Web of Science | Medline6
Kurtzke JF . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452
Web of Science | Medline7
Pocock SJ ,Simon R . Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-115
CrossRef | Web of Science | Medline8
Losseff NA ,Wang L ,Lai HM , et al. Progressive cerebral atrophy in multiple sclerosis: a serial MRI study. Brain 1996;119:2009-2019
CrossRef | Web of Science | Medline9
Cobbold SP ,Rebello PR ,Davies HF ,Friend PJ ,Clark MR . A simple method for measuring patient anti-globulin responses against isotypic or idiotypic determinants. J Immunol Methods 1990;127:19-24
CrossRef | Web of Science | Medline10
Lin DY ,Wei LJ ,Yang I ,Ying Z . Semiparametric regression for the mean and rate functions of recurrent events. J R Stat Soc [B] 2000;62:711-730
CrossRef11
Laupacis A ,Sackett DL ,Roberts RS . An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988;318:1728-1733
Full Text | Web of Science | Medline12
Lachin JM . Some large-sample distribution-free estimators and tests for multivariate partially incomplete data from two populations. Stat Med 1992;11:1151-1170
CrossRef | Web of Science | Medline13
Wei LJ ,Lachin JM . Two-sample asymptotically distribution-free tests for incomplete multivariate observations. J Am Stat Assoc 1984;79:653-661
CrossRef | Web of Science14
PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group
CrossRef | Web of Science | Medline15
Jacobs LD ,Cookfair DL ,Rudick RA , et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294[Erratum, Ann Neurol 1996;40:480.]
CrossRef | Web of Science | Medline16
IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group
Web of Science | Medline17
Johnson KP ,Brooks BR ,Cohen JA , et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995;45:1268-1276
Web of Science | Medline18
Paty DW ,Li DK . Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667
Web of Science | Medline19
Moreau T ,Coles A ,Wing M , et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996;119:225-237
CrossRef | Web of Science | Medline20
Goodin DS ,Frohman EM ,Garmany GP Jr , et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:169-178[Erratum, Neurology 2002;59:480.]
Web of Science | Medline21
Hauser SL ,Waubant E ,Arnold DL , et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-688
Full Text | Web of Science | Medline22
Kappos L ,Antel J ,Comi G , et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124-1140
Full Text | Web of Science | Medline23
Hsiao LT ,Liu JH ,Yen CC , et al. Relapse of Graves' disease after successful allogeneic bone marrow transplantation. Bone Marrow Transplant 2001;28:1151-1153
CrossRef | Web of Science | Medline24
Gilquin J ,Viard J ,Jubault V ,Sert C ,Kazatchkine MD . Delayed occurrence of Graves' disease after immune restoration with HAART: highly active antiretroviral therapy. Lancet 1998;352:1907-1908
CrossRef | Web of Science | Medline25
Kirby S ,Brown MG ,Murray TJ , et al. Prevalence of other autoimmune diseases in patients with multiple sclerosis. Mult Scler 2005;11:S29-S29
Web of Science26
Granier H ,Bellard S ,Nicolas X ,Laborde JP ,Talarmin F . Association of multiple sclerosis and autoimmune thrombopenia. Rev Med Interne 2001;22:1271-1272
CrossRef | Web of Science | Medline27
Segal JB ,Powe NR . Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost 2006;4:2377-2383
CrossRef | Web of Science | Medline28
Munteis E ,Segura N ,Martinez J ,Cuadrado E ,Galvez A ,Roquer J . Idiopathic thrombocytopenic purpura in patients with multiple sclerosis. Mult Scler 2006;12:S210-S210
CrossRef | Web of Science29
Otton SH ,Turner DL ,Frewin R ,Davies SV ,Johnson SA . Autoimmune thrombocytopenia after treatment with Campath 1H in a patient with chronic lymphocytic leukaemia. Br J Haematol 1999;106:261-262
CrossRef | Web of Science | Medline30
Haider I ,Cahill M . Fatal thrombocytopaenia temporally related to the administration of alemtuzumab (MabCampath) for refractory CLL despite early discontinuation of therapy. Hematology 2004;9:409-411
CrossRef | Medline31
Loh Y ,Oyama Y ,Statkute L , et al. Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used. Blood 2007;109:2643-2548
CrossRef | Web of Science | Medline32
Jones JL ,Thompson S ,Cox AL ,Compston DAS ,Coles AJ . Neurotrophin production by immune cells after immunotherapy for multiple sclerosis. J Neuroimmunol 2004;154:212-212
Web of Science
- Citing Articles (162)
Citing Articles
1
Daniel Ontaneda, Megan Hyland, Jeffrey A. Cohen. (2012) Multiple Sclerosis: New Insights in Pathogenesis and Novel Therapeutics. Annual Review of Medicine 63:1, 389-404
CrossRef2
Peter Connick, Madhan Kolappan, Charles Crawley, Daniel J Webber, Rickie Patani, Andrew W Michell, Ming-Qing Du, Shi-Lu Luan, Daniel R Altmann, Alan J Thompson, Alastair Compston, Michael A Scott, David H Miller, Siddharthan Chandran. (2012) Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. The Lancet Neurology 11:2, 150-156
CrossRef3
Jin Nakahara, Michiko Maeda, Sadakazu Aiso, Norihiro Suzuki. (2012) Current Concepts in Multiple Sclerosis: Autoimmunity Versus Oligodendrogliopathy. Clinical Reviews in Allergy & Immunology 42:1, 26-34
CrossRef4
David H Miller, Thomas Weber, Richard Grove, Claire Wardell, Joseph Horrigan, Ole Graff, Gillian Atkinson, Pinky Dua, Tarek Yousry, David MacManus, Xavier Montalban. (2012) Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet Neurology 11:2, 131-139
CrossRef5
N. C. Hare, D. P. J. Hunt, K. Venugopal, G.- T. Ho, T. Beez, C. W. Lees, R. Gibson, B. Weller, J. Satsangi. (2012) Multiple sclerosis in the context of TNF blockade and inflammatory bowel disease. QJM
CrossRef6
Lawrence Steinman, Joan T Merrill, Iain B McInnes, Mark Peakman. (2012) Optimization of current and future therapy for autoimmune diseases. Nature Medicine 18:1, 59-65
CrossRef7
Henrik Gensicke, David Leppert, Özgür Yaldizli, Raija L.P. Lindberg, Matthias Mehling, Ludwig Kappos, Jens Kuhle. (2012) Monoclonal Antibodies and Recombinant Immunoglobulins for the Treatment of Multiple Sclerosis. CNS Drugs 26:1, 11-37
CrossRef8
Nikolaos Stathatos, Gilbert H. Daniels. (2012) Autoimmune thyroid disease. Current Opinion in Rheumatology 24:1, 70-75
CrossRef9
David Baker, Gareth Pryce, Samuel J. Jackson, Chris Bolton, Gavin Giovannoni. (2012) The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis. Multiple Sclerosis and Related Disorders
CrossRef10
Marina A. Lynch, Kingston H.G. Mills. (2012) Immunology meets neuroscience – Opportunities for immune intervention in neurodegenerative diseases. Brain, Behavior, and Immunity 26:1, 1-10
CrossRef11
Fred D. Lublin. (2012) Disease activity free status in MS. Multiple Sclerosis and Related Disorders 1:1, 6-7
CrossRef12
Shiv Saidha, Christopher Eckstein, Peter A. Calabresi. (2012) New and emerging disease modifying therapies for multiple sclerosis. Annals of the New York Academy of Sciencesno-no
CrossRef13
A. Cuker, A. J. Coles, H. Sullivan, E. Fox, M. Goldberg, P. Oyuela, A. Purvis, D. S. Beardsley, D. H. Margolin. (2011) A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Blood 118:24, 6299-6305
CrossRef14
A. Saxena, G. Martin-Blondel, L.T. Mars, R.S. Liblau. (2011) Role of CD8 T cell subsets in the pathogenesis of multiple sclerosis. FEBS Letters 585:23, 3758-3763
CrossRef15
Alan M. Palmer. (2011) Immunomodulatory medicines for multiple sclerosis: Progress and prospects. Drug Development Research 72:8, 664-673
CrossRef16
O.-P. R. Hamnvik, P. R. Larsen, E. Marqusee. (2011) Thyroid Dysfunction from Antineoplastic Agents. JNCI Journal of the National Cancer Institute 103:21, 1572-1587
CrossRef17
Jean Kwun, Pinar Bulut, Eugenia Kim, Wasim Dar, Byoungchol Oh, Ravi Ruhil, Neal Iwakoshi, Stuart J. Knechtle. (2011) The role of B cells in solid organ transplantation. Seminars in Immunology
CrossRef18
Richard Haynes, Peter Friend. (2011) Alemtuzumab: right drug, right dose?*. Transplant International 24:11, 1051-1052
CrossRef19
J. Sastre-Garriga, X. Montalban. (2011) Anticuerpos monoclonales en desarrollo en esclerosis múltiple. Neurología 26:9, 556-562
CrossRef20
Jeremy Chataway, David H Miller. (2011) Multiple sclerosis—quenching the flames of inflammation. The Lancet 378:9805, 1759-1760
CrossRef21
Ludwig Kappos, David Li, Peter A Calabresi, Paul O'Connor, Amit Bar-Or, Frederik Barkhof, Ming Yin, David Leppert, Robert Glanzman, Jeroen Tinbergen, Stephen L Hauser. (2011) Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. The Lancet 378:9805, 1779-1787
CrossRef22
J. Sastre-Garriga, X. Montalban. (2011) Monoclonal antibodies in development in multiple sclerosis. Neurología (English Edition) 26:9, 556-562
CrossRef23
Oscar Fernández. (2011) Nuevos fármacos para el tratamiento de la esclerosis múltiple. FMC - Formación Médica Continuada en Atención Primaria 18:9, 582-588
CrossRef24
Duncan Graham-Rowe. (2011) Antibody offers hope for multiple sclerosis treatment. Nature
CrossRef25
T. Menge, B.C. Kieseier, C. Warnke, O. Aktas, H.-P. Hartung. (2011) Alemtuzumab: eine weitere Chance zur Therapie der Multiplen Sklerose. Der Nervenarzt
CrossRef26
Mark Sanford, Katherine A. Lyseng-Williamson. (2011) Subcutaneous Recombinant Interferon-β-1a (Rebif®). Drugs 71:14, 1865-1891
CrossRef27
David Gosselin, Serge Rivest. (2011) Immune Mechanisms Underlying the Beneficial Effects of Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. Neurotherapeutics 8:4, 643-649
CrossRef28
Dorothea Buck, Bernhard Hemmer. (2011) Treatment of multiple sclerosis: current concepts and future perspectives. Journal of Neurology 258:10, 1747-1762
CrossRef29
Brian Healy, Tanuja Chitnis, David Engler. (2011) Improving power to detect disease progression in multiple sclerosis through alternative analysis strategies. Journal of Neurology 258:10, 1812-1819
CrossRef30
Jeffrey K. Huang, Stephen P. J. Fancy, Chao Zhao, David H. Rowitch, Charles ffrench-Constant, Robin J. M. Franklin. (2011) Myelin Regeneration in Multiple Sclerosis: Targeting Endogenous Stem Cells. Neurotherapeutics 8:4, 650-658
CrossRef31
E. J. Fox, H. C. Sullivan, S. K. Gazda, L. Mayer, L. O’Donnell, K. Melia, S. L. Lake. (2011) A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis. European Journal of Neurologyno-no
CrossRef32
T. Hayton, J. Furby, K. J. Smith, D. R. Altmann, R. Brenner, J. Chataway, K. Hunter, D. J. Tozer, D. H. Miller, R. Kapoor. (2011) Clinical and imaging correlates of the multiple sclerosis impact scale in secondary progressive multiple sclerosis. Journal of Neurology
CrossRef33
Gillian M. Bell, Gary Reynolds, John D. Isaacs. (2011) Biologic therapies in non-rheumatic diseases: lessons for rheumatologists?. Nature Reviews Rheumatology 7:9, 507-516
CrossRef34
F. Zipp, R. Gold. (2011) Neuroprotektion in der Therapie der Multiplen Sklerose. Der Nervenarzt 82:8, 973-977
CrossRef35
Bernard M.J. Uitdehaag, Frederik Barkhof, Patricia K. Coyle, Jason D. Gardner, Douglas R. Jeffery, Daniel D. Mikol. (2011) The changing face of multiple sclerosis clinical trial populations. Current Medical Research and Opinion 27:8, 1529-1537
CrossRef36
Xavier Poiré, Koen van Besien. (2011) Alemtuzumab in allogeneic hematopoetic stem cell transplantation. Expert Opinion on Biological Therapy 11:8, 1099-1111
CrossRef37
George P. Christophi, Jennifer A. Christophi, Ross C. Gruber, Cornelia Mihai, Luis J. Mejico, Paul T. Massa, Burk Jubelt. (2011) Quantitative differences in the immunomodulatory effects of Rebif and Avonex in IFN-β 1a treated multiple sclerosis patients. Journal of the Neurological Sciences 307:1-2, 41-45
CrossRef38
Gilles Edan, Emmanuelle Leray. (2011) A new treatment era in multiple sclerosis: Clinical applications of new concepts. Journal of the Neurological Sciences 306:1-2, 170-172
CrossRef39
Daniel R Getts, Sushma Shankar, Emily ML Chastain, Aaron Martin, Meghann Teague Getts, Kathryn Wood, Stephen D Miller. (2011) Current landscape for T-cell targeting in autoimmunity and transplantation. Immunotherapy 3:7, 853-870
CrossRef40
Alessandra Vultaggio, Enrico Maggi, Andrea Matucci. (2011) Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management. Current Opinion in Allergy and Clinical Immunology 11:3, 262-268
CrossRef41
Hans-Peter Hartung, Helmar C. Lehmann, Bernd C. Kieseier, Richard A. C. Hughes. (2011) Novel treatment for immune neuropathies on the horizon. Journal of the Peripheral Nervous System 16:2, 75-83
CrossRef42
James J. Marriott, Paul W. O’Connor. (2011) Definitions of Breakthrough Disease and Second-Line Agents. Neurologic Clinics 29:2, 411-422
CrossRef43
Gavin Giovannoni. (2011) Promising Emerging Therapies for Multiple Sclerosis. Neurologic Clinics 29:2, 435-448
CrossRef44
Bernd C. Kieseier, Olaf Stüve. (2011) A critical appraisal of treatment decisions in multiple sclerosis—old versus new. Nature Reviews Neurology 7:5, 255-262
CrossRef45
Adil Javed, Betty Soliven. (2011) Fingolimod: a novel oral immunomodulatory treatment for multiple sclerosis. Future Neurology 6:3, 315-325
CrossRef46
G. Martin-Blondel, P. Delobel, A. Blancher, P. Massip, B. Marchou, R. S. Liblau, L. T. Mars. (2011) Pathogenesis of the immune reconstitution inflammatory syndrome affecting the central nervous system in patients infected with HIV. Brain 134:4, 928-946
CrossRef47
Alasdair J Coles, Edward Fox, Anton Vladic, Suzanne K Gazda, Vesna Brinar, Krzysztof W Selmaj, Ann Doan-Do Bass, Daniel R Wynn, David H Margolin, Stephen L Lake, Susan Moran, Jeffrey Palmer, M Shelton Smith, D Alastair S Compston. (2011) Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. The Lancet Neurology 10:4, 338-348
CrossRef48
Hans-Peter Hartung, Orhan Aktas. (2011) Evolution of multiple sclerosis treatment: next generation therapies meet next generation efficacy criteria. The Lancet Neurology 10:4, 293-295
CrossRef49
Luisa Klotz, Sven G. Meuth, Heinz Wiendl. (2011) Immune mechanisms of new therapeutic strategies in multiple sclerosis—A focus on alemtuzumab. Clinical Immunology
CrossRef50
Hans-Peter Hartung, Xavier Montalban, Per Soelberg Sorensen, Patrick Vermersch, Tomas Olsson. (2011) Principles of a new treatment algorithm in multiple sclerosis. Expert Review of Neurotherapeutics 11:3, 351-362
CrossRef51
Daniel Harrison, Douglas E Gladstone. (2011) High-dose chemotherapy and multiple sclerosis. Current Opinion in Oncology 23:2, 221-226
CrossRef52
Aaron E. Miller. (2011) Multiple Sclerosis: Where Will We Be in 2020?. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 78:2, 268-279
CrossRef53
Stephen Krieger. (2011) Multiple Sclerosis Therapeutic Pipeline: Opportunities and Challenges. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 78:2, 192-206
CrossRef54
Xavier Bosch, Albert Saiz, Manuel Ramos-Casals. (2011) Monoclonal antibody therapy-associated neurological disorders. Nature Reviews Neurology 7:3, 165-172
CrossRef55
Cris S Constantinescu, Nasr Farooqi, Kate O'Brien, Bruno Gran. (2011) Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). British Journal of Pharmacologyno-no
CrossRef56
C. Kuhn, S. You, F. Valette, G. Hale, P. van Endert, J.-F. Bach, H. Waldmann, L. Chatenoud. (2011) Human CD3 Transgenic Mice: Preclinical Testing of Antibodies Promoting Immune Tolerance. Science Translational Medicine 3:68, 68ra10-68ra10
CrossRef57
Christine Stadelmann, Christiane Wegner, Wolfgang Brück. (2011) Inflammation, demyelination, and degeneration — Recent insights from MS pathology. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1812:2, 275-282
CrossRef58
Jeffrey K. Huang, Robin J.M. Franklin. (2011) Regenerative medicine in multiple sclerosis: Identifying pharmacological targets of adult neural stem cell differentiation. Neurochemistry International
CrossRef59
Elie Dolgin. (2011) Genzyme, though unique, could be a bellwether for US biotech. Nature Medicine 17:2, 145-145
CrossRef60
Peter Connick, Madhan Kolappan, Rickie Patani, Michael A Scott, Charles Crawley, Xiao-Ling He, Karen Richardson, Kelly Barber, Daniel J Webber, Claudia AM Wheeler-Kingshott, Daniel J Tozer, Rebecca S Samson, David L Thomas, Ming-Qing Du, Shi L Luan, Andrew W Michell, Daniel R Altmann, Alan J Thompson, David H Miller, Alastair Compston, Siddharthan Chandran. (2011) The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments. Trials 12:1, 62
CrossRef61
Christopher W. Mitchell, Tulio E. Bertorini. 2011. Principles and Guidelines of Immunotherapy in Neuromuscular Disorders. , 101-113.
CrossRef62
Peter Wipfler, Andrea Harrer, Georg Pilz, Katrin Oppermann, Eugen Trinka, Jörg Kraus. (2011) Recent developments in approved and oral multiple sclerosis treatment and an update on future treatment options. Drug Discovery Today 16:1-2, 8-21
CrossRef63
D. Spoerl, Andreas J. Bircher. 2011. Drugs that act on the immune system. , 769-814.
CrossRef64
Peter O. Behan, Abhijit Chaudhuri. (2010) The sad plight of multiple sclerosis research (low on fact, high on fiction): critical data to support it being a neurocristopathy. Inflammopharmacology 18:6, 265-290
CrossRef65
Amy Perrin Ross, Ben W. Thrower. (2010) Recent Developments in the Early Diagnosis and Management of Multiple Sclerosis. Journal of Neuroscience Nursing 42:6, 342-353
CrossRef66
H Atkins. (2010) Hematopoietic SCT for the treatment of multiple sclerosis. Bone Marrow Transplantation 45:12, 1671-1681
CrossRef67
Edward J Fox. (2010) Alemtuzumab in the treatment of relapsing–remitting multiple sclerosis. Expert Review of Neurotherapeutics 10:12, 1789-1797
CrossRef68
Anthony Slavin, Louise Kelly-Modis, Mark Labadia, Kelli Ryan, Maryanne L. Brown. (2010) Pathogenic mechanisms and experimental models of multiple sclerosis. Autoimmunity 43:7, 504-513
CrossRef69
Arnd Heiligenhaus, Stephan Thurau, Maren Hennig, Rafael S. Grajewski, Gerhild Wildner. (2010) Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease. Graefe's Archive for Clinical and Experimental Ophthalmology 248:11, 1531-1551
CrossRef70
James T Rosenbaum. (2010) Future for biological therapy for uveitis. Current Opinion in Ophthalmology 21:6, 473-477
CrossRef71
Rebecca Manno, Francesco Boin. (2010) Immunotherapy of systemic sclerosis. Immunotherapy 2:6, 863-878
CrossRef72
László Maródi, Jean-Laurent Casanova. (2010) Primary immunodeficiencies may reveal potential infectious diseases associated with immune-targeting mAb treatments. Journal of Allergy and Clinical Immunology 126:5, 910-917
CrossRef73
Clare J. Fowler, Catherine Dalton, Jalesh N. Panicker. (2010) Review of Neurologic Diseases for the Urologist. Urologic Clinics of North America 37:4, 517-526
CrossRef74
Lawrence Steinman, Scott S. Zamvil. (2010) Delivery of myelin peptides through the first line of defense, skin, to counter autoimmunity in multiple sclerosis. Annals of Neurology 68:5, 567-569
CrossRef75
M. Filippi, M. A. Rocca, D. L. Arnold, R. Bakshi, F. Barkhof, N. De Stefano, F. Fazekas, E. Frohman, D. H. Miller, J. S. Wolinsky. 2010. Use of Imaging in Multiple Sclerosis. , 35-51.
CrossRef76
Herman Waldmann. (2010) Tolerance: an overview and perspectives. Nature Reviews Nephrology 6:10, 569-576
CrossRef77
Allan D. Kirk, Nicole A. Turgeon, Neal N. Iwakoshi. (2010) B cells and transplantation tolerance. Nature Reviews Nephrology 6:10, 584-593
CrossRef78
Adrian R Kendal, Herman Waldmann. (2010) Infectious tolerance: therapeutic potential. Current Opinion in Immunology 22:5, 560-565
CrossRef79
Trung Huynh. (2010) The multiple sclerosis market. Nature Reviews Drug Discovery 9:10, 759-760
CrossRef80
Jin Nakahara, Sadakazu Aiso, Norihiro Suzuki. (2010) Autoimmune Versus Oligodendrogliopathy: The Pathogenesis of Multiple Sclerosis. Archivum Immunologiae et Therapiae Experimentalis 58:5, 325-333
CrossRef81
Charlotte L. M. Krieckaert, G. Margret Bartelds, Gerrit-Jan Wolbink. (2010) Therapy: Immunogenicity of biologic therapies—we need tolerance. Nature Reviews Rheumatology 6:10, 558-559
CrossRef82
Rachel A. Farrell, Gavin Giovannoni. (2010) Current and Future Role of Interferon Beta in the Therapy of Multiple Sclerosis. Journal of Interferon & Cytokine Research 30:10, 715-726
CrossRef83
J. M. Fletcher, S. J. Lalor, C. M. Sweeney, N. Tubridy, K. H. G. Mills. (2010) T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clinical & Experimental Immunology 162:1, 1-11
CrossRef84
, O. Fernández, V. Fernández, T. Arbizu, G. Izquierdo, I. Bosca, R. Arroyo, J. A. García Merino, E. Ramón. (2010) Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (The Novo Study). Journal of Neurology 257:9, 1500-1507
CrossRef85
K. Rejdak, S. Jackson, G. Giovannoni. (2010) Multiple sclerosis: a practical overview for clinicians. British Medical Bulletin 95:1, 79-104
CrossRef86
J. Furby, T. Hayton, D. Altmann, R. Brenner, J. Chataway, K. J. Smith, D. H. Miller, R. Kapoor. (2010) A longitudinal study of MRI-detected atrophy in secondary progressive multiple sclerosis. Journal of Neurology 257:9, 1508-1516
CrossRef87
Joanne L. Jones, Alasdair J. Coles. (2010) New treatment strategies in multiple sclerosis. Experimental Neurology 225:1, 34-39
CrossRef88
Rina Aharoni. (2010) Immunomodulatory drug treatment in multiple sclerosis. Expert Review of Neurotherapeutics 10:9, 1423-1436
CrossRef89
Stephen P.J. Fancy, Mark R. Kotter, Emily P. Harrington, Jeffrey K. Huang, Chao Zhao, David H. Rowitch, Robin J.M. Franklin. (2010) Overcoming remyelination failure in multiple sclerosis and other myelin disorders. Experimental Neurology 225:1, 18-23
CrossRef90
Kristen M Gawronski, Michelle M Rainka, Malti J Patel, Francis M Gengo. (2010) Treatment Options for Multiple Sclerosis: Current and Emerging Therapies. Pharmacotherapy 30:9, 916-927
CrossRef91
Clare E. Buckley, Anita Marguerie, Alan G. Roach, Paul Goldsmith, Angeleen Fleming, Wendy K. Alderton, Robin J.M. Franklin. (2010) Drug reprofiling using zebrafish identifies novel compounds with potential pro-myelination effects. Neuropharmacology 59:3, 149-159
CrossRef92
Faye A.H. Cooles, John D. Isaacs. (2010) Treating to re-establish tolerance in inflammatory arthritis – lessons from other diseases. Best Practice & Research Clinical Rheumatology 24:4, 497-511
CrossRef93
H. Wekerle, R. Hohlfeld. (2010) Beneficial brain autoimmunity?. Brain 133:8, 2182-2184
CrossRef94
Marcelo C. Pasquini, Linda M. Griffith, Douglas L. Arnold, Harold L. Atkins, James D. Bowen, Jacqueline T. Chen, Mark S. Freedman, George H. Kraft, Gian Luigi Mancardi, Roland Martin, Paolo A. Muraro, Richard A. Nash, Michael K. Racke, Jan Storek, Riccardo Saccardi. (2010) Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: Collaboration of the CIBMTR and EBMT to Facilitate International Clinical Studies. Biology of Blood and Marrow Transplantation 16:8, 1076-1083
CrossRef95
J. L. Jones, J. M. Anderson, C.-L. Phuah, E. J. Fox, K. Selmaj, D. Margolin, S. L. Lake, J. Palmer, S. J. Thompson, A. Wilkins, D. J. Webber, D. A. Compston, A. J. Coles. (2010) Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain 133:8, 2232-2247
CrossRef96
William M. Siders, Jacqueline Shields, Carrie Garron, Yanping Hu, Paula Boutin, Srinivas Shankara, William Weber, Bruce Roberts, Johanne M. Kaplan. (2010) Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models. Leukemia & Lymphoma 51:7, 1293-1304
CrossRef97
Giuseppe Barbesino. (2010) Drugs Affecting Thyroid Function. Thyroid 20:7, 763-770
CrossRef98
Sreeram V Ramagopalan, Ruth Dobson, Ute C Meier, Gavin Giovannoni. (2010) Multiple sclerosis: risk factors, prodromes, and potential causal pathways. The Lancet Neurology 9:7, 727-739
CrossRef99
Peter O Behan. (2010) Futility of the autoimmune orthodoxy in multiple sclerosis research. Expert Review of Neurotherapeutics 10:7, 1023-1025
CrossRef100
E. Leray, J. Yaouanq, E. Le Page, M. Coustans, D. Laplaud, J. Oger, G. Edan. (2010) Evidence for a two-stage disability progression in multiple sclerosis. Brain 133:7, 1900-1913
CrossRef101
Christian Schütz, Mathias Oelke, Jonathan P Schneck, Andreas Mackensen, Martin Fleck. (2010) Killer artificial antigen-presenting cells: the synthetic embodiment of a ‘guided missile’. Immunotherapy 2:4, 539-550
CrossRef102
Qingyong Ji, Antoine Perchellet, Joan M Goverman. (2010) Viral infection triggers central nervous system autoimmunity via activation of CD8+ T cells expressing dual TCRs. Nature Immunology 11:7, 628-634
CrossRef103
Reza Vosoughi, Mark S. Freedman. (2010) Therapy of MS. Clinical Neurology and Neurosurgery 112:5, 365-385
CrossRef104
E. A. Marsh, C. L. Hirst, J. G. Llewelyn, M. D. Cossburn, M. M. Reilly, A. Krishnan, M. Doran, A. M. Ryan, A. J. Coles, J. L. Jones, N. P. Robertson. (2010) Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. Journal of Neurology 257:6, 913-919
CrossRef105
M. Buttmann, H. Wiendl. (2010) Therapeutische monoklonale Antikörper in der Neurologie. Der Nervenarzt 81:6, 753-766
CrossRef106
Jennifer A Tracy, P James B Dyck. (2010) Investigations and treatment of chronic inflammatory demyelinating polyradiculoneuropathy and other inflammatory demyelinating polyneuropathies. Current Opinion in Neurology 23:3, 242-248
CrossRef107
Yolanda S. Kap, Jon D. Laman, Bert A. ‘t Hart. (2010) Experimental Autoimmune Encephalomyelitis in the Common Marmoset, a Bridge Between Rodent EAE and Multiple Sclerosis for Immunotherapy Development. Journal of Neuroimmune Pharmacology 5:2, 220-230
CrossRef108
Mathias Buttmann. (2010) Treating multiple sclerosis with monoclonal antibodies: a 2010 update. Expert Review of Neurotherapeutics 10:5, 791-809
CrossRef109
L. Steinman. (2010) Inverse vaccination, the opposite of Jenner’s concept, for therapy of autoimmunity. Journal of Internal Medicine 267:5, 441-451
CrossRef110
Andrew C. Chan, Paul J. Carter. (2010) Therapeutic antibodies for autoimmunity and inflammation. Nature Reviews Immunology 10:5, 301-316
CrossRef111
Thomas H Brannagan, Shanna K Patterson. (2010) Alemtuzumab: the future of chronic inflammatory demyelinating polyradiculoneuropathy treatment?. Expert Review of Clinical Immunology 6:3, 319-321
CrossRef112
B. Sharrack, T. Jenkins. (2010) Disease modifying therapies in multiple sclerosis. International Journal of Clinical Practice 64:5, 532-534
CrossRef113
Trevor T. Hansel, Harald Kropshofer, Thomas Singer, Jane A. Mitchell, Andrew J. T. George. (2010) The safety and side effects of monoclonal antibodies. Nature Reviews Drug Discovery 9:4, 325-338
CrossRef114
S. Y. Lim, C. S. Constantinescu. (2010) Current and future disease-modifying therapies in multiple sclerosis. International Journal of Clinical Practice 64:5, 637-650
CrossRef115
Orhan Aktas, Bernd Kieseier, Hans-Peter Hartung. (2010) Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends in Neurosciences 33:3, 140-152
CrossRef116
Jack C Sipe. (2010) Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis. Expert Review of Neurotherapeutics 10:3, 365-375
CrossRef117
Nancy L Kuntz, Dorothee Chabas, Bianca Weinstock-Guttman, Tanuja Chitnis, E Ann Yeh, Lauren Krupp, Jayne Ness, Moses Rodriguez, Emmanuelle Waubant. (2010) Treatment of multiple sclerosis in children and adolescents. Expert Opinion on Pharmacotherapy 11:4, 505-520
CrossRef118
Lucienne Chatenoud. (2010) Immune therapy for type 1 diabetes mellitus—what is unique about anti-CD3 antibodies?. Nature Reviews Endocrinology 6:3, 149-157
CrossRef119
Tom Button, Alasdair J Coles. (2010) Alemtuzumab for the treatment of multiple sclerosis. Future Neurology 5:2, 177-188
CrossRef120
Carroll, William M., . (2010) Oral Therapy for Multiple Sclerosis — Sea Change or Incremental Step?. New England Journal of Medicine 362:5, 456-458
Full Text121
Yi-chi M. Kong, Wei-Zen Wei, Yaron Tomer. (2010) Opportunistic autoimmune disorders. Annals of the New York Academy of Sciences 1183:1, 222-236
CrossRef122
Masaaki Niino, Hidenao Sasaki. (2010) Update on the treatment options for multiple sclerosis. Expert Review of Clinical Immunology 6:1, 77-88
CrossRef123
Kate O’Brien, Bruno Gran, Abdolmohamad Rostami. (2010) T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunotherapy 2:1, 99-115
CrossRef124
Sara A. J. Thompson, Joanne L. Jones, Amanda L. Cox, D. Alastair S. Compston, Alasdair J. Coles. (2010) B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis. Journal of Clinical Immunology 30:1, 99-105
CrossRef125
E William St Clair. (2009) Novel targeted therapies for autoimmunity. Current Opinion in Immunology 21:6, 648-657
CrossRef126
Olaf Stüve. (2009) Knowns and unknowns in the future of multiple sclerosis treatment. Journal of the Neurological Sciences 287, S30-S36
CrossRef127
Massimo Filippi, Paul O'Connor. (2009) Do interferon beta-1b and glatiramer acetate grow brain? – Authors' reply. The Lancet Neurology 8:12, 1086-1087
CrossRef128
Richard A Rudick, Elizabeth Fisher. (2009) Do interferon beta-1b and glatiramer acetate grow brain?. The Lancet Neurology 8:12, 1085-1086
CrossRef129
Anthony Weetman. (2009) Immune reconstitution syndrome and the thyroid. Best Practice & Research Clinical Endocrinology & Metabolism 23:6, 693-702
CrossRef130
John H Pula, Adil Javed. (2009) Multiple sclerosis. Part 2: Ophthalmic issues in MS therapy. Current Opinion in Ophthalmology 20:6, 476-481
CrossRef131
Yanping Hu, Michael J. Turner, Jacqueline Shields, Matthew S. Gale, Elizabeth Hutto, Bruce L. Roberts, William M. Siders, Johanne M. Kaplan. (2009) Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 128:2, 260-270
CrossRef132
David H Miller, Siobhan M Leary. (2009) Treatment of clinically isolated syndrome: to be PreCISe. The Lancet 374:9700, 1475-1476
CrossRef133
Stephen M Anderton. 2009. Immunological Tolerance: Therapeutic Induction. .
CrossRef134
R. Dam-Tuxen, E. Riise. (2009) Antibodies against a Class II HLA-Peptide Complex Raised by Active Immunization of Mice with Antigen Mimicking Peptides. Scandinavian Journal of Immunology 70:2, 93-100
CrossRef135
Thomas Dörner, Andreas Radbruch, Gerd R. Burmester. (2009) B-cell-directed therapies for autoimmune disease. Nature Reviews Rheumatology 5:8, 433-441
CrossRef136
Manuel A. Friese, Lars Fugger. (2009) Pathogenic CD8 + T cells in multiple sclerosis. Annals of Neurology 66:2, 132-141
CrossRef137
B. Stemper. (2009) Alemtuzumab bei Multipler Sklerose. Der Nervenarzt 80:S1, 62-63
CrossRef138
Terri M. Laufer, Gregory F. Wu. (2009) Treating MS: getting to know the two birds in the bush. Journal of Clinical Investigation
CrossRef139
Joanne L. Jones, Chia-Ling Phuah, Amanda L. Cox, Sara A. Thompson, Maria Ban, Jacqueline Shawcross, Amie Walton, Stephen J. Sawcer, Alastair Compston, Alasdair J. Coles. (2009) IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). Journal of Clinical Investigation
CrossRef140
Lars Fugger, Manuel A. Friese, John I. Bell. (2009) From genes to function: the next challenge to understanding multiple sclerosis. Nature Reviews Immunology 9:6, 408-417
CrossRef141
Marco Salvetti, Gavin Giovannoni, Francesca Aloisi. (2009) Epstein–Barr virus and multiple sclerosis. Current Opinion in Neurology 22:3, 201-206
CrossRef142
M. C. Dalakas, G. Rakocevic, J. Schmidt, M. Salajegheh, B. McElroy, M. O. Harris-Love, J. A. Shrader, E. W. Levy, J. Dambrosia, R. L. Kampen, D. A. Bruno, A. D. Kirk. (2009) Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 132:6, 1536-1544
CrossRef143
Martin Stangel. (2009) Multiple sclerosis: Hematopoietic stem cell transplantation: hope and hype. Nature Reviews Neurology 5:6, 300-302
CrossRef144
Bert A. ‘t Hart, Rogier Q. Hintzen, Jon D. Laman. (2009) Multiple sclerosis – a response-to-damage model. Trends in Molecular Medicine 15:6, 235-244
CrossRef145
Paul S Giacomini, Peter J Darlington, Amit Bar-Or. (2009) Emerging multiple sclerosis disease-modifying therapies. Current Opinion in Neurology 22:3, 226-232
CrossRef146
John W. Rose, John F. Foley, Noel G. Carlson. (2009) Monoclonal antibody treatments for multiple sclerosis. Current Treatment Options in Neurology 11:3, 211-220
CrossRef147
Krupa Pandey, Fred D. Lublin. (2009) Clinically isolated syndrome and multiple sclerosis: Rethinking the arsenal. Current Treatment Options in Neurology 11:3, 193-202
CrossRef148
J Ludovic Croxford, Takashi Yamamura. (2009) Back to the future for multiple sclerosis therapy: focus on current and emerging disease-modifying therapeutic strategies. Immunotherapy 1:3, 403-423
CrossRef149
Stephen P Cobbold. (2009) Future therapeutics for the induction of peripheral immune tolerance in autoimmune disease and organ transplantation. Immunotherapy 1:3, 447-460
CrossRef150
C. Warnke, B.C. Kieseier, U. Zettl, H-P. Hartung. (2009) Alemtuzumab als neue Therapieoption der Multiplen Sklerose. Der Nervenarzt 80:4, 468-474
CrossRef151
A. A. Pace, J. P. Zajicek. (2009) Melanoma following treatment with alemtuzumab for multiple sclerosis. European Journal of Neurology 16:4, e70-e71
CrossRef152
Joseph R. Berger, Sidney Houff. (2009) Opportunistic infections and other risks with newer multiple sclerosis therapies. Annals of Neurology 65:4, 367-377
CrossRef153
Howard L. Weiner. (2009) The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease?. Annals of Neurology 65:3, 239-248
CrossRef154
Aimee Pasqua Borazanci, Meghan K Harris, Robert N Schwendimann, Eduardo Gonzalez-Toledo, Amir H Maghzi, Masoud Etemadifar, Nadejda Alekseeva, James Pinkston, Roger E Kelley, Alireza Minagar. (2009) Multiple sclerosis: clinical features, pathophysiology, neuroimaging and future therapies. Future Neurology 4:2, 229-246
CrossRef155
Patricia K Coyle. (2009) Existing therapies for multiple sclerosis offer proven efficacy and safety. Current Opinion in Neurology 22:Suppl 1, S4-S9
CrossRef156
(2009) Alemtuzumab limits multiple sclerosis but is associated with autoimmune complications. Nature Clinical Practice Neurology 5:1, 4-4
CrossRef157
Matthew Kaufman, Sewanti A. Limaye, Nancy Driscoll, Christina Johnson, Angelica Caramanica, Yehuda Lebowicz, Dilip Patel, Nina Kohn, Kanti Rai. (2009) A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia. Leukemia & Lymphoma 50:6, 892-899
CrossRef158
Henry F McFarland. (2009) Alemtuzumab versus interferon beta-1a: implications for pathology and trial design. The Lancet Neurology 8:1, 26-28
CrossRef159
Randy Osborne. (2009) Buzz around Campath proof-of-concept trial in MS. Nature Biotechnology 27:1, 6-8
CrossRef160
Heather J MacLean, Mark S Freedman. (2009) Multiple sclerosis: following clues from cause to cure. The Lancet Neurology 8:1, 6-8
CrossRef161
(2008) News in brief. Nature Medicine 14:12, 1296-1297
CrossRef162
Hauser, Stephen L., . (2008) Multiple Lessons for Multiple Sclerosis. New England Journal of Medicine 359:17, 1838-1841
Full Text
